Ulevostinag  (Synonyms: MK-1454)

Ulevostinag (MK-1454) is a potent cyclic dinucleotide agonist stimulator of interferon genes (STING). Ulevostinag (MK-1454) acts in the intra-tumoral route by targeting the stimulator of interferon genes (STING) protein. Ulevostinag (MK-1454) can be used for immuno-tumor cancer disease research^[1].

Ulevostinag (MK-1454) (5 μg, 20 μg for intratumorally) can activate tumor-specific immune responses in MC38 injected tumors and inhibit tumor growth at untreated, distal sites^[1].
Ulevostinag (MK-1454) (4 μg for intratumorally on day 0, 3 and 7) results in complete tumor regression and enhances the efficacy of anti-PD1 therapy in MC38 and B16F10 tumor mice model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

710.52

C₂₀H₂₂F₂N₁₀O₉P₂S₂

2082743-96-0

Solid

White to off-white

F[C@H]1[C@](O[P@](S)(OC[C@](O[C@](N2C3=NC=NC(N)=C3N=C2)([H])[C@H]4F)([H])[C@@]4([H])O5)=O)([H])[C@@](N6C(NC(N)=NC7=O)=C7N=C6)([H])O[C@]1([H])CO[P@]5(S)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zawit M, et al. Current status of intralesional agents in treatment of malignant melanoma. Ann Transl Med. 2021 Jun;9(12):1038.  [Content Brief]

  [2]. Gogoi H, et al. The Age of Cyclic Dinucleotide Vaccine Adjuvants. Vaccines (Basel). 2020 Aug 13;8(3):453.  [Content Brief]

  [3]. Chang W, et al. Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer. J Med Chem. 2022 Apr 14;65(7):5675-5689.  [Content Brief]